Reducing Post-Mastectomy Disparities in Breast Cancer Minority Populations
A study evaluating disparities in breast reconstructive surgery sought to assess the impact of culture, race, and ethnicity in minority groups.
Related Articles
[Reactivation of cytomegalovirus and its influencing factors in patients with B-lymphocyte malignancy after CAR-T cell therapy] – PubMed
Objective: This study aimed to analyze cytomegalovirus (CMV) reactivation and its influencing factors in patients with B-lymphocyte malignancy who received chimeric antigen receptor T (CAR-T)…
Safety and efficacy of CD33-targeted CAR-NK cell therapy for relapsed/refractory AML: preclinical evaluation and phase I trial – PubMed
NCT05008575 ( https://clinicaltrials.gov/study/NCT05008575 ).
29th Annual Acute Leukemia Forum 2025 | La Jolla, California
Register now and explore groundbreaking advancements in acute leukemia and myelodysplasia treatment at ALF 2025. Stay informed with the latest innovations shaping the future of…
Prominent efficacy and good safety of sequential CD19 and CD22 CAR-T therapy in relapsed/refractory adult B-cell acute lymphoblastic leukemia – PubMed
Sequential CAR-T cell therapy demonstrated durable efficacy and a manageable safety profile in R/R B-ALL, providing a viable option to address antigen-loss relapse and improve…
100-mg Bezuclastinib Improves Symptoms, Biomarkers in Non-Advanced Systemic Mastocytosis
Treatment with a 100-mg dose of bezuclastinib had a favorable safety and tolerability profile in patients with non-advanced systemic mastocytosis.
ctDNA and beyond to serve immunotherapy
Recent findings consolidate the role of liquid biopsy in the field, but prospective research is needed
How newer bispecifics, including teclistamab & talquetamab, may influence myeloma treatment
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, comments on the potential of bispecific antibodies in multiple myeloma, specifically…
MAIC Points to Improved OS With Momelotinib in Ruxolitinib-Pretreated Myelofibrosis
Momelotinib improved OS vs best available therapy in patients with ruxolitinib-experienced myelofibrosis, according to data from a MAIC analysis.
Real-World OS Outcomes Are Similar for Frontline CDK4/6 Inhibitor Combos in HR+, HER2– Breast Cancer
Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.
The OncFive: Top Oncology Articles for the Week of 12/18
Fixed-duration acalabrutinib combination improves PFS in CLL, imlunestrant ± abemaciclib boosts PFS in ESR1-mutated ER+ breast cancer, and more.